HRA-19(人結(jié)腸癌腺癌細(xì)胞)
產(chǎn)品類別:人源細(xì)胞系
生長特性:Adherent
細(xì)胞形態(tài):Epithelial
凍存條件:90%FBS+10%DMSO
Synonyms: HRA-19(人結(jié)腸癌腺癌細(xì)胞)
Background: The HRA-19 cell line was established from a primary human rectal adenocarcinoma present in a 66-year old male. The adenocarcinoma was well differentiated and determined to be Dukes' stage B. A clonal derivative of HRA-19 is available (HRA-19a1.1, ECACC catalogue number 09071517). HRA-19 has stem cell properties and undergoes a multilineage differentiation in serum free medium. A number of genetically modified derivatives of HRA-19 are also available.
Species: human (Homo sapiens)
Tissue: Rectum
Disease: Human colorectal adenocarcinoma
Gender: 66-year old male,UK
Morphology: Epithelial
Growth Mode: Adherent
Doubling Time: N/A
DNA Profile: Amelogenin: X,Y
CSF1PO: 12
D13S317: 11,12
D16S539: 11
D5S818: 11
D7S820: 9,12
THO1: 8
TPOX: 11
vWA: 16
Cell Line Authentication Service
Culture Medium: DMEM+10%FBS
We strongly suggest to purchase the complete medium
Cryopreservation medium: 90%FBS+10%DMSO
Karyotype: Not specified
Subculture Routine: Split sub-confluent cultures (70-80%) 1:5 to 1:10 weekly using 0.0125% trypsin/EDTA; 7.5% CO2; 37°C.Suggested seeding density 2-4x10,000 cells/cm2.